Skip to main content

Table 1 Summary of patients’ clinical characteristics

From: Retrospective study comparing MR-guided radiation therapy (MRgRT) setup strategies for prostate treatment: repositioning vs. replanning

Age (years)

Mean (range)

77 (65–86)

T stage

T1

2 (10.5%)

T2

11 (57.9%)

T3

2 (10.5)

T4

4 (21.1%)

GS score

6 (3 + 3)

3 (15.8%)

7 (3 + 4)

3 (15.8%)

7 (4 + 3)

5 (26.3%)

8 (4 + 4)

7 (36.8%)

9 (4 + 5)

1 (5.3%)

aPSA

Median (range)

18.89 (2.19–161.95)

Mean (SD)

27.78 (35.63)

bADT use

10 (52.63%)

  1. aPSA prostate-specific antigen; bADT androgen deprivation therapy